A score model for the continuous grading of early allograft dysfunction severity.

Area of Science:

• Transplantation immunology
• Graft survival analysis
• Clinical decision modeling

Background:

• Early allograft dysfunction (EAD) significantly impacts liver transplant outcomes.
• Lack of a standardized EAD definition complicates outcome comparisons and recipient management.
• Quantitative assessment is needed for early allograft function.

Purpose of the Study:

• To develop and validate a quantitative model for assessing early allograft function (MEAF score).
• To establish a standardized definition for EAD to enable reliable comparisons.
• To identify key factors associated with EAD.

Main Methods:

• Retrospective analysis of 1026 liver transplant cases for model development.
• Multivariate analysis to identify key postoperative variables for EAD assessment.
• Mathematical modeling of clinical parameters (ALT, INR, bilirubin) to create the MEAF score (0-10).
• Validation on an independent cohort of 200 liver transplant recipients.

Main Results:

• The MEAF score demonstrated significant associations with patient and graft survival at 3, 6, and 12 months.
• Donor factors (hepatic steatosis, age), surgical factors (ischemia times, postreperfusion syndrome), and recipient factors (ICU/hospital stay, MELD/Child-Pugh scores, BMI, FFP transfusions) were linked to EAD.
• The MEAF model showed satisfactory validation in an independent cohort.

Conclusions:

• The MEAF score offers a validated, quantitative assessment of EAD severity, surpassing current categorical definitions.
• MEAF aids in early decision-making regarding retransplantation and predicts patient/graft survival.
• Standardizing EAD criteria via MEAF facilitates reliable comparisons of transplant outcomes and treatments.